MOB — Moberg Pharma AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK434.29m
- SEK213.93m
- SEK13.54m
Brief: Moberg Pharma's Chairman Peter Wolpert Not Available For Re-Election
Brief: Moberg Pharma Q3 EBITDA Loss Narrows To SEK 4.0 Million
Brief: Moberg Pharma Partners With Allderma For Launch In Scandinavia
Brief: Moberg Pharma Receives Approval From The EMA's Paediatric Committee
Brief: Moberg Pharma Q2 EBITDA Loss Narrows To SEK 3.5 Mln
Brief: Moberg Pharma Q1 EBITDA Loss Widens To SEK 5.4 Million
Brief: Oncozenge Has Been Approved For Listing On Nasdaq First North Growth Market
Brief: Moberg Pharma: OncoZenge Gets Conditional Approval For Listing On Nasdaq First North Growth Market
Brief: Moberg Pharma Unit Announces Issue Of European Patent Related To BupiZenge
Brief: Moberg Pharma Rights Issue Gets Fully Subscribed
Brief: Moberg Pharma: OncoZenge Raises SEK 10 Mln Ahead Of Spin-Off And Separate Listing
Brief: Moberg Pharma Announces Final Terms Of Fully Guaranteed Rights Issue
Brief: Moberg Pharma: OncoZenge Secures About SEK 70 Mln In Financing Ahead Of Spin-Off And Separate Listing
Brief: Moberg Pharma July-Sept EBITDA Turns To Profit Of SEK 24.4 Mln
Brief: Moberg Pharma Intends To Distribute And Separately List Bupizenge
Brief: Moberg Pharma Decides On Fully Guaranteed Rights Issue Of About SEK 150 Million
Brief: Moberg Pharma Q4 EBITDA Loss At SEK 5.7 Million
Brief: Moberg Pharma - Appointment Of Chief Medical Officer
Brief: Moberg Pharma Meets Primary Endpoint In The European Phase 3 Study